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Fabian P. Alvarezc
aYork Health Economics Consortium, Enterprise House, University of York, York, UK; bSanofi Pasteur UK & Ireland, Reading, UK; cSanofi
Pasteur, Lyon, France
ABSTRACT
Aims: High dose trivalent influenza vaccine (HD TIV) and adjuvant TIV (aTIV) have been developed
specifically for adults aged 65 and older (65þ) who are at high risk of life-threatening complications.
However, there is a scarcity of evidence comparing the clinical and cost-effectiveness of HD TIV and
aTIV. The aim of this study was to determine the cost-effectiveness of HD TIV versus aTIV in the
England and Wales 65þ population.
Methods: A cost-utility analysis was conducted using a decision tree with two influenza related out-
comes: Laboratory confirmed cases that could result in GP consultation, and hospitalizations that may
result in premature mortality. Due to a lack of comparative evidence, the effectiveness of HD TIV ver-
sus aTIV was calculated indirectly, based on relative effectiveness estimates for each vaccine versus a
common comparator, standard dose (SD) TIV. The primary analysis included hospitalizations explicitly
due to influenza/pneumonia. Cost-effectiveness was established for three scenarios applying differing
relative effectiveness estimates for aTIV versus SD TIV. Uncertainty was analysed in one-way determin-
istic sensitivity analyses. A secondary analysis included hospitalizations due to any respiratory illness.
Results: The minimum population impact of vaccination with HD TIV rather than aTIV was 13,092
fewer influenza cases, 1,109 fewer influenza related deaths, 4,673 fewer hospitalizations, and 3,245
fewer GP appointments. HD TIV was cost-effective versus aTIV for all three effectiveness scenarios,
with incremental cost-effectiveness ratios (ICER) equal to £1,932, £4,181, and £8,767 per quality
adjusted life year. Results were consistent across the secondary analysis and deterministic sensitiv-
ity analyses.
Limitations: The analysis was limited by a lack of robust and consistent effectiveness data for aTIV.
Conclusion: HD TIV is cost-effective versus aTIV in people aged 65þ in England and Wales. Use of HD
TIV over aTIV could increase clinical benefits and reduce the public health and economic burden
of influenza.
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Influenza vaccination programmes are a public health prior-
ity, particularly for older adult populations who are at higher
risk of complications including lower respiratory tract infec-
tion, hospitalization, and death1. Seasonal flu epidemics are
typically caused by influenza type A (subtypes H1N1 and
H3N2) and different type B viruses2. Consequently, the World
Health Organization (WHO) currently recommend vaccines
containing multiple type A and B antigens, for example inac-
tivated trivalent (TIV) and quadrivalent influenza vaccines
(QIV)3. The standard dose influenza vaccination typically con-
tains 15 mg of antigen per strain. In a meta-analysis of 10
randomized controlled trials (RCTs), standard dose trivalent
vaccines (SD TIV, FluzoneVR , Sanofi Pasteur) had an
effectiveness in healthy adults of around 59%, which varied
substantially across influenza seasons and subtypes4.
The effectiveness of standard dose vaccines is diminished
in older populations likely due to immune system functional-
ity and antibody response which declines naturally with
advancing age5. To address issues of reduced effectiveness,
specific vaccine formulations have been developed in adults
65 years of age and older, herein referred to as 65þ. A high
dose trivalent influenza vaccine (HD TIV, FluzoneVR High-Dose,
Sanofi Pasteur), which contains 60 mg of haemagglutinin (HA)
antigen per strain, generates higher antibody responses and
greater effectiveness than SD influenza vaccines6,7: Evidence
from a phase IIIb–IV, multi-centre, double blinded RCT dem-
onstrated that HD TIV is more efficacious versus SD TIV in
adults 65þ8, a finding which has been consistently
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supported by multiple observational studies9–18 and a meta-
analysis covering over 12 million HD TIV recipients across
nine influenza seasons6,19. Furthermore, standard dose vac-
cines are not recommended by the Joint Committee on
Vaccination and Immunization (JCVI). Instead, high dose and
adjuvanted vaccines are recommended for adults 65þ20.
Adjuvant TIV (aTIV, Flaud, Seqirus) contains 15 mg HA anti-
gen per strain with the addition of MF59 oil-in-water emulsion
of squalene oil21. There is a scarcity of data comparing aTIV
with active vaccines in RCTs and moreover there is inconsist-
ency in observational study findings published in the litera-
ture. Four out of six observational studies included in a
systematic review did not identify statistically significant differ-
ences between aTIV and other SD influenza vaccines22; and a
recent case control study in the UK did not identify significant
benefits for aTIV versus non-adjuvant vaccines for the 2018/19
influenza season23. Furthermore, a systematic literature review
by the European Centre for Disease Prevention and Control
found no statistical difference in relative effectiveness
between aTIV and non-adjuvanted TIV and QIV vaccines in
adult populations24. Therefore, the in vivo benefits of aTIV
remain uncertain. Furthermore, a recent randomized clinical
trial found that aQIVs failed to demonstrate superiority versus
a non-influenza vaccine in older adults during seasons with
high amounts of vaccine strain mismatch25.
The respective difference in the evidence profiles for HD
TIV and aTIV is reflected in assessments made by the
National Advisory Committee on Immunization in Canada
(NACI). In a literature review, NACI states that there is good
quality, “grade A”, evidence indicating superiority for high
dose vaccines versus SD TIV, whereas the effectiveness evi-
dence for adjuvant vaccines versus unadjuvanted vaccines is
“insufficient”26. A retrospective cohort study on more than
12 million fee-for-service US Medicare beneficiaries found
high-dose egg-based vaccines were not significantly different
to adjuvanted egg-based vaccines, which was 7.5% more
effective than standard (i.e. nonadjuvanted) vaccines12. A
second retrospective cohort study of over 2 million people
aged 65þ in the USA indicates HD TIV may be up to 12%
more effective than aTIV in preventing respiratory related
hospitalizations27.
If HD TIV is effective over aTIV, its preferential use in the
65þ population could reduce the impact of influenza and
may have public health implications, particularly by reducing
hospitalizations and early mortality which are key contribu-
tors to the overall economic burden of influenza28.
Aims and objectives
The main objective of this analysis was to determine the
cost-effectiveness of HD TIV versus aTIV for adults 65þ in
England and Wales from a UK healthcare perspective by uti-
lizing the best available evidence to date. A further objective
was to explore cost-effectiveness results across several deter-
ministic scenarios, thus accounting for uncertainty in the
effectiveness evidence for aTIV. In addition, we established
the cost-effectiveness of HD TIV versus aTIV for (i) a primary
analysis which defined hospitalizations explicitly due to
influenza/pneumonia and (ii) a secondary analysis which
included all hospitalizations due to any lower respira-
tory infection.
Methods
Model perspective and structure
This was a cost-utility analysis, adopting a UK healthcare per-
spective including costs incurred by the NHS and Prescribed
Specialized Services (PSS) and health benefits as quality
adjusted life years (QALYs). The analysis estimated the incre-
mental cost-effectiveness ratio (ICER) of HD TIV versus aTIV,
assuming a cost-effectiveness threshold (CE threshold)
between £20,000 and £30,000 per QALY, as stipulated in the
NICE reference case29.
We constructed a decision tree to compare the cost-
effectiveness of HD TIV with aTIV over a single influenza sea-
son. The decision tree included two disease pathways following
vaccination: (i) Laboratory confirmed influenza (LCI) cases that
could result in a general practitioner (GP) visit and (ii) hospital
stays which could lead to premature death (Figure 1). The pri-
mary analysis defined hospitalizations specifically due to influ-
enza or pneumonia which was expanded to include all
respiratory related hospitalizations in a secondary analysis. The
two disease pathways were not mutually exclusive,i meaning
populations could enter one, both, or neither following vaccin-
ation. The model was conducted over a single average influ-
enza season. A lifetime horizon for QALYs was adopted by
establishing life expectancies for populations who were dis-
charged from hospital and to a third non-disease pathway who
were neither LCI cases nor hospital attendees. To avoid double
counting we included influenza related mortality as an out-
come on the hospitalization, but not the LCI, disease pathway.
Target population
The target population included adults 65þ in England and
Wales stratified into three groups according to their age and
risk of influenza-related complications: (i) People aged 65–74
with chronic respiratory disease or chronic heart disease,
who are defined as “high risk” as their underlying condition
predisposes them to influenza related complications; (ii) peo-
ple aged 65–74 without underlying medical conditions who
are at relatively lower risk of complications; and (iii) all peo-
ple aged 75 and over including both low and high-risk
groups. Age groups were analysed separately due to differ-
ences in vaccination coverage, vaccination effectiveness, and
the likelihood of GP or hospital attendance if infected. Due
to limitations in available data it was only possible to differ-
entiate the age 65–74 risk groups by likelihood of GP attend-
ance. Mean costs and QALYs were calculated independently
for each of the three populations. Cost-effectiveness results
were pooled across the full population of over 65s by calcu-
lating a weighted average across the stratified age and risk
groups. We also report cost-effectiveness results separately
for the 65–74 (pooled across high and low risk) and 75þ age
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groups. Population parameters by age and risk group are
reported in Table 1.
Model parameters
Vaccination coverage
The model included both vaccinated and unvaccinated pop-
ulations. The probability of vaccination was estimated for
each age and risk group separately. To establish the percent-
age of the population receiving the HD TIV and aTIV vaccin-
ation we applied typical coverage rates as described in
Public Health England Annual Flu reports30, equal to 62.7%
in people aged 65–74 (for both low and high and risk
groups), and 80% in the 75þ age group.
Probability of lab confirmed influenza
To calculate the probability of LCI in the unvaccinated
cohort, we applied a baseline influenza attack rate of 7.50%,
this being the mid-point of global influenza attack rates
(between 5% and 10%) reported by the World Health
Organization for all adult populations, that is, not specific for
populations aged 65þ31. Probabilities for the vaccinated
cohort were calculated by multiplying the baseline influenza
attack rate for the unvaccinated cohort by the vaccine effect-
iveness (VE) of HD TIV and aTIV versus no vaccination.
Probability of hospitalization
The probability of hospitalization was calculated using age
stratified rates for pneumonia and influenza related
Figure 1. Structure of the decision tree. #Laboratory confirmed cases of influenza.  Pneumonia/influenza related hospitalizations (primary analysis), hospitaliza-
tions due to any respiratory cause (secondary analysis).
Table 1. Model input parameters by age and risk group.
Parameter Input value Source
Age 65–74 (low risk) Age 65–74 (high risk) Age 75þ (all risk)
Population parameters:
Population size 3,171,289 2,594,691 4,751,498 ONS55
Vaccination coverage rate 62.7% 62.7% 80.0% Public Health England56
Influenza attack rate (unvaccinated)a 7.5% 7.5% 7.5% Assumption based on WHO31
Hospitalization rate per 100,000 (SD TIV) 190.65 190.65 898.29 Observational study32
Clinical outcomes probabilities
GP Visit j Influenza diagnosis 20.2% 30.4% 24.8% UK burden of illness study40
Death j hospitalization 13.0% 13.0% 26.0% UK Observational Study41
Death j no hospitalization 1.4% 1.4% 5.2% ONS life tables42
aInfluenza attack rate obtained for all adult population (i.e. not specific for populations aged 65þ).
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hospitalizations, defined as ICD10 codes J09-J18, from a lon-
gitudinal study32. We applied a single baseline probability for
hospitalization across both the vaccinated and unvaccinated
cohorts as the original study32 utilized Clinical Practice
Research Database (CPRD) and Hospital Episode Statistics
(HES) data, therefore establishing rates in a UK population
where SD TIV was available. Probabilities for the vaccinated
cohort were then adjusted based on VE for HD TIV and aTIV
versus no vaccination.
Vaccination effectiveness
The key inputs into the economic model were: (i) VE, which
measures the proportion reduction in cases among vacci-
nated versus unvaccinated populations; and (ii) relative vac-
cine effectiveness (rVE), which measures the proportion
reduction in cases for populations vaccinated with one vac-
cine relative to another vaccine. Due to restrictions in data
availability, VE for both HD TIV and aTIV (versus no vaccin-
ation) were estimated indirectly by rearranging rVE estimates
for HD TIV and aTIV versus SD TIV and VE estimates for SD
TIV (versus no vaccination).ii
We calculated the VE for SD TIV on LCI cases as a
weighted average across influenza A, matched B, and mis-
matched B. The VE for influenza type A and matched B were
both equal to 46% based on a pooled estimate across both
lineages in observational evidence across the 2005–2008 UK
influenza seasons33. The mismatched status of influenza B
was defined as a poor match between the vaccine and the
circulating strain. Consequently, mismatched influenza B was
assigned a reduced VE of 28% based on a published cost-
effectiveness study34. To pool VE for SD TIV, we estimated
the mean percentage of circulating influenza virus from
annual Public Health England (2010–2017) influenza reports
as equal to 78% for influenza A, 10.7% for matched influenza
B, and 11.3% for mismatched influenza B30. The VE for SD
TIV on hospitalizations could not be disaggregated and was
set equal to 28% across all strains and subtypes based on a
published cost-effectiveness study34.
The rVE against lab-confirmed influenza of HD TIV versus
SD TIV for the LCI pathway was sourced from a phase 3b/IV
randomized efficacy trial and equal to 24.2%8. Meanwhile,
the rVE for HD TIV versus SD TIV on hospitalization endpoints
was equal to 24.3%, this being obtained from a meta-analysis
informed by two RCTs and three observational studies and
covering multiple influenza seasons6. The rVE estimates indi-
cate that for every 100 influenza cases in populations vacci-
nated with SD TIV, there would be roughly 76 cases in
populations vaccinated with HD TIV (i.e. a 24% reduction).
Despite large observational studies being conducted to
evaluate the effectiveness of influenza vaccines12, due to
inconsistent results from season to season22, randomized
clinical trials (RCTs) remain the gold standard when assessing
vaccine efficacy. Therefore, the economic model used values
from RCTs whenever available.
The 2021 St€andige Impfkommission (STIKO) guideline sys-
tematic review and the 2020 European Centre for Disease
Prevention and Control (ECDC) systematic review both identi-
fied one RCT reporting on rVE of HD-TIV compared with con-
ventional vaccination in LCI. The rVE of aTIV in preventing
LCI was compared only with unvaccinated populations or
standard dose vaccines in non-randomized studies35,36. No
RCTs or observational studies compared aTIV and HD-TIV dir-
ectly35,36. Due to this scarcity of trial-based evidence and
heterogeneous findings from observational studies, three dif-
ferent rVE scenarios were investigated for aTIV versus SD TIV.
The base case (scenario 1) applied an rVE of 0% on both LCI
and hospitalization endpoints reflecting NACI evidence
assessments and the non-significant differences identified
between aTIV and SD TIV in multiple observational stud-
ies22,23,26. The second scenario applied an rVE of 6% on LCI
endpoints based on a non-significant effect size from a
Spanish observational study37, and assumed an rVE of 10%
on hospitalization endpoints.iii Finally, scenario 3 applied the
largest rVE effectiveness estimates of 12% on LCI and 20%
on hospitalization endpoints: The former estimate was
informed by an observational study in an Italian population38
which has been challenged for its academic quality by
NACI26; the latter estimate mirrored an assumption in a pub-
lished economic model assessing the cost-effectiveness of
aTIV versus SD TIV, however this was not based on either
Table 2. Vaccine effectiveness/relative vaccine effectiveness.
Vaccine Input parameter Input value Source
Base case (scenario 1) Scenario 2 Scenario 3
HD TIV rVE vs SD TIV (LCI) 24.2% 24.2% 24.2% RCT8
rVE vs SD TIV (hospitalization) 24.3% 24.3% 24.3% Meta-Analysis6
aTIV rVE vs SD TIV (LCI) 0% 10% 20% See belowa
rVE vs SD TIV (hospitalizations) 0% 6% 12% See belowb
SD TIVc VE (matched LCI)d 46% 46% 46% Public Health England (PHE) economic model34
VE (mismatched LCI)e 28% 28% 28% Public Health England (PHE) economic model34
VE (hospitalizations)f 28% 28% 28% Public Health England (PHE) economic model34
aaTIV rVE versus LCI: S1 assumed based on non-significant effects from observational evidence22; S2 mid-point assumption based on no clinical or observational
evidence; S3 assumption mirroring estimate applied in cost-effectiveness study based on no clinical or observational evidence39.
baTIV rVE versus pneumonia hospitalization: S1: Assumed based on non-significant effects from observational evidence22; S2: Assumption from an observational
study37, the outcome was non-significant rVE versus influenza hospitalization (actual trial endpoint did not specify pneumonia); S3: Observational study38 out-
come non-significant rVE for the full influenza season.
cAll VE for SD TIV is versus no vaccination.
dVE for SD TIV versus no vaccination for matched influenza type A and type B.
eVE for SD TIV versus no vaccination for mismatched influenza type B.
fVE for SD TIV versus no vaccination on hospitalizations endpoint. Actual endpoint is “influenza complications”, not specifying pneumonia hospitalizations, but
such data is not available.
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RCT or observational data39. All VE and rVE for the base case
and scenario analyses are summarized in Table 2.
Probability of general practitioner visits
We calculated the probability of GP attendance following LCI
separately for the 65–74 and 75þ age groups by dividing
the total number of GP attendances due to influenza by the
total number of people in the population with influenza (i.e.
influenza attack rate multiplied by total population size).
Data for the numerator were sourced from a published linear
regression analysis estimating the total number of people in
England and Wales who attended influenza related GP
appointments. This was stratified by age in a database utiliz-
ing Hospital Episode Statistics (HES)40.
Probability of mortality
The probability of premature mortality following hospitaliza-
tion was obtained directly from published literature which
used HES data to estimate the percentage of patients who
died following hospitalization for influenza or pneumonia by
age group, defining cases by ICD-10 code (J09-18iv)41. We
obtained age-group specific absolute risks of mortality due
to any cause from age- and gender-weighted life tables pub-
lished by the Office for National Statistics42.
Quality adjusted life years
We calculated gender weighted life expectancies by age
group using the mortality data from UK life tables to estab-
lish the expected remaining life years for subjects who sur-
vived the influenza season42. Total quality adjusted life years
(QALYs) were then calculated by aggregating health utilities
across subjects’ remaining life years whilst incorporating util-
ity reductions for any LCI cases or hospitalizations. Baseline
utility values by age group are reported in Table 3 and were
obtained from the published literature based on self-
reported UK EQ-5D scores43. We applied utility reductions
per LCI case using influenza specific utility values from an
HTA report44 and assuming a duration of infection equal to
6 days. The total disutility per influenza related hospitaliza-
tion was obtained from a published cost-effectiveness ana-
lysis which reported summed QALY detriments for hospital
patients with uncomplicated influenza like illness and
pneumococcal pneumonia34. All QALYs occurring after 12-
months were discounted at 3.5%.
Unit costs
All unit costs are reported in Table 3. Vaccination costs for
HD TIV and aTIV were obtained from Sanofi/Seqirus list pri-
ces and applied to the proportion of the population who
received the vaccination (i.e. the vaccination coverage rate).
All administration costs were excluded as this was an incre-
mental analysis and both vaccination procedures and cover-
age rates were assumed to be equivalent. GP consultation
costs were obtained from a published UK based cost-effect-
iveness analysis which reported the mean primary care staff
and prescription costs (2008GB£) per influenza episode utiliz-
ing the General Practice Research Database45. Costs
(2008GB£) per hospitalisation were taken from the same
cost-effectiveness study, which calculated the mean length
of stay for all LCI hospitalizations (ICD code J10) by daily
NHS reference costs (tariff DZ11B for lobar, atypical or viral
pneumonia without complications)45. All unit costs from pub-
lished literature were inflated to 2018 values using the
Hospital and Community Services Pay and Prices index46.
Discounting was not required for costs as these occurred
across a single influenza season, within a year of vaccination.
Uncertainty analysis
Uncertainty was investigated for the primary analysis using
one-way deterministic sensitivity analyses (DSA) which indi-
vidually varied input parameters and recalculated ICERs
according to the altered values. The DSA was limited to the
scenario with the highest efficacy rates for aTIV. A Tornado
plot was generated with parameter ranges equal to 95%
confidence intervals or ±15% of the mean if confidence
intervals were not available. The DSA included scenarios
which reduced the rVE of HD TIV versus SD TIV from (i)
24.3% to 17% for influenza related hospitalizations, and (ii)
24.2% to 9.70% for LCI cases. In addition, we investigated
uncertainty around HD TIV vaccination costs by identifying
the economically justifiable price (EJP). We calculated the EJP
by identifying the maximum price at which HD TIV remained
cost-effective, that is, achieved an ICER below the CE thresh-
old of £20,000 and £30,000 per QALY.
Table 3. Unit costs (2018 GB£) and QALYs.
Parameter Input value Source
Costs
Cost per aTIV vaccine £9.79 List Prices
Cost per HD TIV vaccine £20.00 List Prices
Cost per GP consultation £103.9 CE Analysis45
Cost per hospitalization £5,633.53 CE Analysis45
Quality adjusted life years
Utility general population (65–74 only) 0.773 Published self-report EQ-5D scores43
Utility general population (75þ only) 0.703 Published self-report EQ-5D scores43
Utility (influenza) 0.2947 HTA report44
Disutility (hospitalization) 0.018 CE Analysis34
Mean influenza duration (days) 6 Assumption
Mean life expectancy (year)
Age 64–75 80.8 Calculation based on ONS UK Life Tables42
Age 75þ 88.3
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A secondary analysis was also conducted which expanded
the influenza and pneumonia hospitalizations outcome to
include hospitalizations due to any lower respiratory infec-
tion. Whilst providing a less specific endpoint for influenza,
the outcome was selected for the secondary analysis to
include data from a retrospective observational study which
directly compared the rVE of HD TIV and aTIV27. For the sec-
ondary analysis, we estimated rates of hospitalization by age
group using HES databases including all non-elective admis-
sions with primary respiratory diagnosis (defined as ICD10
codes J00-J99) in four November–May influenza seasons
between 2015 and 201847. Vaccine efficacy rates for HD TIV
and aTIV (versus no vaccination) were calculated by rearrang-
ing equations for rVE of HD TIV versus aTIV and VE for SD
TIV (Table 4).v
Results
Primary analysis: pneumonia/influenza hospitalizations
High dose TIV was found to be cost-effective in adults aged
65þ in England and Wales when compared with aTIV,
assuming the lower CE threshold estimate equal to £20,000
(Table 5). The results for the primary analysis were robust
across all three aTIV influenza/pneumonia hospitalization
effectiveness scenarios with ICERs equal to £1,932 per QALY
for the base case (scenario 1), £4,181 per QALY for scenario
2, and £8,767 per QALY for scenario 3.vi
The net impact of HD TIV versus aTIV on population
health and NHS costs is displayed in Table 6. Across a single
influenza season, HD TIV was predicted to result in substan-
tially fewer cases of laboratory confirmed influenza, hospital-
izations, and influenza-related deaths when compared with
populations vaccinated with aTIV. Across the lifetime, HD TIV
achieved 11,460 (scenario 1), 8,539 (scenario 2), and 5,618
(scenario 3) additional QALYs when compared with aTIV.
Populations who received HD TIV had a higher total cost
burden, with incremental population costs versus aTIV equal
to £22,144,118 (scenario 1), £35,700,436 (scenario 2), and
£49,256,755 (scenario 3). Differences in healthcare costs were
driven by higher vaccination costs for HD TIV, which
exceeded cost savings attributable to reductions in primary
and secondary healthcare resources required for influenza
treatment (Table 6).
The EJP analysis indicated that uncertainty in the price of
HD TIV was not likely to impact on the cost-effectiveness
findings. The price of HD TIV could be increased from £20.00
(list price) to £47.91 (scenario 1), £38.21 (scenario 2), and
£28.50 (scenario 3) whilst remaining cost-effective versus
aTIV at a CE threshold of £20,000 per QALY. When applying
a CE threshold of £30,000 per QALY, the EJP of HD TIV
increased to £63.37 (scenario 1), £49.72 (scenario 2), and
£36.08 (scenario 3).
Table 4. Model inputs used in the secondary analysis (all respiratory hospitalizations).
Parameter Input Source
Hospitalization rates per 100,000
65–74 years 1,638 HES 2015–201857
75þ years 4,577
Vaccine effectiveness (versus respiratory hospitalizations)
TIV SD 30% Assumption
rVE TIV HD vs TIV SD 27% Correspondence with authors of RCT8
rVE TIV HD vs aTIV 12% Observational study27
Cost per hospitalization (2018, GB£) £2,920 Analysis using HES 2017/2018 data (unpublished)
Table 5. Cost-effectiveness results for HD TIV versus aTIV (2018 GB£).
Primary analysisa (influenza/pneumonia hospitalizations) Secondary analysis (respiratory hospitalizations)
Base case (scenario 1) Scenario 2 Scenario 3
Incremental costs (population) £22,144,118 £35,700,436 £49,256,755 £13,685,101
Incremental QALYs (population) 11,460 8,539 5,618 4,888
ICER (£/QALY) £1,932 £4,181 £8,767 £2,800
Total hospitalizations avoided 9,161 6,899 4,637 21,128
Cost per hospitalization avoided £2,417 £5,175 £10,622 £647
aResults aggregated across all population groups aged 65þ (65–74 low risk; 65–74 high risk; 75þ all risk).
Table 6. Net population impact of HD TIV and aTIV for one influenza season (2018 GB£).
aTIV HD TIV
Base case (scenario 1) Scenario 2 Scenario 3
Vaccination costs £72,607,220 £72,607,220 £72,607,220 £148,329,357
Prescription costs £168,614 £158,958 £149,301 £145,245
Cost of GP visits £14,026,024 £13,222,753 £12,419,482 £12,082,108
Hospitalization costs £302,380,130 £289,636,739 £276,893,347 £250,769,395
Total healthcare costs £389,181,989 £375,625,670 £362,069,351 £411,326,107
Influenza cases 544,292 513,120 481,949 468,857
GP visits 134,892 127,166 119,441 116,196
Hospitalizations 53,675 51,413 49,151 44,514
Influenza related deaths 12,526 11,985 11,444 10,335
1266 R. MATTOCK ET AL.
Age group specific results (primary analysis, base
case scenario)
Results for the primary analysis and base case rVE for aTIV
differed when stratifying populations by age group. The ICER
for HD TIV versus aTIV decreased when populations were
restricted to those aged 75 years and older, therefore remain-
ing cost-effective at CE thresholds <£20,000 for all scenarios.
In contrast, the ICERs increased when populations were lim-
ited to those aged 65–74: HD TIV remained cost-effective for
the rVE aTIV effectiveness assumption in scenarios 1 and 2
but was not cost-effective for scenario 3 where ICERs
exceeded the upper CE threshold of £30,000. The difference
in results across age groups was driven by higher rates of
hospitalization for people aged over 75 resulting in substan-
tially more hospitalizations avoided for populations who
received HD TIV (Table 7).
Secondary analysis (all respiratory hospitalizations)
Cost-effectiveness results were robust for the secondary ana-
lysis, which used direct rVE evidence for HD TIV versus aTIV
on expanded endpoints including all respiratory hospitaliza-
tions. The ICER for HD TIV versus aTIV was equal to £2,800,
with incremental population costs equal to £13,685,101 and
incremental lifetime population QALYs equal to 4,888. The
economic analysis estimated 21,128 respiratory related hospi-
talizations per influenza season would be avoided if adults
65þ were vaccinated with HD TIV rather than aTIV.
Deterministic sensitivity analysis
Deterministic sensitivity analysis was conducted for aTIV
scenario 3 as this was the most uncertain scenario with an
ICER closest to the CE threshold. Results were robust with
HD TIV remaining cost-effective versus aTIV for all DSA scen-
arios when applying a £30,000 per QALY CE threshold and
all but one DSA scenario when applying the £20,000 per
QALY CE threshold (Figure 2). The DSA identified the rVE of
HD TIV on hospitalization outcomes as an important area of
uncertainty as reducing parameter values from 24.2% (base
case) to 17.17% (DSA low value) increased the ICER to
£26,707. In contrast, the DSA which reduced the rVE of HD
TIV on LCI cases from 24.3% (base case) to 9.70% (DSA low
value) had a minimal impact only increasing the ICER slightly
to £9,562. The DSA identified vaccination costs and hospital-
ization rates as drivers of the cost-effectiveness, meanwhile
Table 7. Cost-effectiveness results by age group: HD TIV versus aTIV (2018 GB£).
Primary analysis (Influenza/Pneumonia hospitalizations)
Base case (scenario 1) Scenario 2 Scenario 3
Age 65–74
Hospitalizations avoided (population) 1,463 1,102 740
Incremental costs (population) £27,712,717 £30,143,609 £32,574,500
Incremental QALYs (population) 1,955 1,424 893
ICER (£/QALY) £14,175 £21,165 £36,460
Age 75þ
Hospitalizations avoided (population) 7,699 5,798 3,897
Incremental costs (population) £5,568,600 £5,556,828 £16,682,255
Incremental QALYs (population) 9,505 7,115 4724.79
ICER (£/QALY) Dominant £781 £3,533
Figure 2. Tornado plot illustrating DSA results for aTIV Scenario 3.  Hospitalization rates varied simultaneously for different age groups: Age 65–74 (low value ¼
135; high value ¼ 247); age 70þ (low value ¼ 634; high value ¼ 1162).
JOURNAL OF MEDICAL ECONOMICS 1267
varying epidemiological utility had a relatively minor impact
on the ICER (Figure 2).
Discussion
This cost-utility analysis using the best available evidence to
date identified HD TIV as cost-effective versus aTIV in popula-
tions aged 65þ, when adopting a healthcare payer perspec-
tive and assuming a CE threshold of £20,000 per QALY. The
additional vaccination costs associated with HD TIV were out-
weighed by substantial benefits achieved through preventing
cases of influenza and subsequent reductions to health mor-
bidity, mortality, and primary and secondary healthcare costs.
Our results are informed by rVE and rely on a positive VE for
SD TIV. The VE for SD TIV may be substantially reduced if
there is a poor match between the vaccine and circulating
influenza strains4. Therefore, our results are most applicable
to future influenza seasons with similar levels of influenza
(78% influenza A, 11% for matched influenza B, and 11%
mismatched B) and VE for SD TIV (46% influenza A, 46%
influenza B, 28% mismatched B).
The results of the uncertainty analysis showed the cost-
effectiveness of HD TIV was robust to changes in the major-
ity of parameter values. Due to the model assumptions, the
rVE of HD TIV versus SD TIV on hospitalizations was a key
driver of cost-effectiveness. However, even when using an
rVE parameter value equal to the lower 95% confidence
interval (as reported in the multi-season influenza meta-ana-
lysis6) the resultant ICER was less than the upper CE thresh-
old of £30,000 per QALY recommended in the NICE
reference case29. Reductions in the number of hospitaliza-
tions are likely to be an important outcome for healthcare
providers, particularly during busy winter seasons when
demand for healthcare and hospital bed days often exceeds
resource supply48.
This is the first economic analysis to compare the cost-
effectiveness of HD TIV with aTIV. Findings from this analysis
could be used to inform future UK vaccination recommenda-
tions which require both clinical and cost-effectiveness evi-
dence. We estimate a substantial reduction in the number of
influenza cases, influenza-related hospitalizations, and influ-
enza-related deaths with a relatively modest increase in vac-
cination costs in adults 65þ who are offered HD TIV rather
than aTIV.
Our model estimated around 500,000 cases of influenza
occur in adults 65þ during a single influenza season in
England and Wales, costing the NHS roughly £400 million
and resulting in 50,000 hospitalizations and over 10,000
deaths. Roughly 70% of the cost burden and over 85% of
influenza related deaths occurred in populations aged 75
and over, despite this age group only containing around
45% of the total population in the model. The increasing
health burden of influenza with age explains results from the
scenario analysis where ICERs for HD TIV versus aTIV were
decreased (i.e. increased cost-effectiveness) when popula-
tions were restricted to the 75 years and older age group.
Based on findings from the published literature we assumed
rates of pneumonia/influenza related hospitalizations are
over four times higher in those aged over 75s when com-
pared with 65–7432, with the older population also twice as
likely to die following hospitalization41.
The population impact of influenza is slightly higher in
our analysis than annual estimates from published burden of
illness studies. Green et al.49 estimated mortality for adults
65þ in England and Wales ranged from 4,000 to 13,000
across six influenza seasons. Matias et al.41 estimated mean
UK influenza deaths and hospitalizations for adults 65þ of
6,270 and 15,214, respectively. Meanwhile, Moss et al.50 cal-
culated UK 18þ hospitalizations due to influenza equal to
46,215 (2017/18) and 39,670 (2018/19). The primary driver of
population outcomes in our model were the influenza attack
rate and hospitalization rate. For HD TIV the DSA applying
the lower attack rate reduced total influenza cases from
468,857 to 312,571 and the DSA applying the lower hospital-
ization rate reduced influenza deaths to 7,297 and hospital-
izations to 31,439. Neither the attack rate nor hospitalization
rate were key drivers of cost-effectiveness as both DSAs
resulted in an ICER below £20,000 per QALY.
This analysis is subject to several limitations. Firstly, our
literature review did not identify any clinical trial which dir-
ectly established the rVE of HD TIV versus aTIV on influenza
and pneumonia hospitalizations, the adopted primary end-
points. This gap is confirmed by the ECDC and STIKO system-
atic reviews that did not find head-to-head studies
comparing aTIV and HD-TIV35,36. Furthermore, both reviews
concur on the scarcity of robust trial data and inconsistency
of published evidence to inform rVE estimates of aTIV versus
SD TIV; hence we could not identify nor conduct a robust
indirect treatment comparison or network meta-analysis. This
was in-line with the STIKO and ECDC guidelines, which only
reported on one RCT estimating efficacy against LCI with
HD-TIV compared with SD-TIV35,36 that we used for model
inputs. Conversely, neither of these groups used observa-
tional studies to assess the impact of HD-TIV against LCI, and
the ECDC guidelines noted that “pooled analyses of effective-
ness data comparing adjuvant with non-adjuvanted vaccines
was restricted by limited study numbers and statistical and
clinical heterogeneity”35. Consequently, vaccine benefits were
estimated using the best available rVE estimates for HD TIV
and aTIV versus a common comparator, SD TIV. The results
from the primary analysis were supported by the secondary
analysis which incorporated direct evidence for HD TIV ver-
sus aTIV on all respiratory hospitalization outcomes. It should
be noted that the ECDC systematic review did identify obser-
vational studies to derive rVE estimates. However, the cost-
effectiveness model in this study used RCT derived inputs
where possible and assessed their uncertainty through sensi-
tivity analysis. This is a limitation of the parameter inclusion
criteria used as part of this study. Future studies are required
to explore the estimated cost-effectiveness of influenza vac-
cines if observational studies were also included to derive
rVE estimates.
Secondly, quadrivalent vaccines (both HD QIV and aQIV)
were not modelled due to a lack of data. However, there is
no reason to assume the comparative findings of HD TIV ver-
sus aTIV should differ from HD QIV versus aQIV. Essink
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et al.51 found that aQIV induces a similar immune response
as aTIV and has a comparable reactogenicity and safety pro-
file. Adjuvant QIV has shown superior immunogenicity over
aTIV against the additional B strain. Similarly, HD QIV is com-
parable to HD TIV in terms of reactogenicity and safety pro-
file, but has a superior induced immune-response to HD
TIV52. Given that the quadrivalent vaccine shows similar
improvements over both the HD TIV and aTIV, it is likely that
what applies for aTIV versus HD TIV will also apply to aQIV
versus HD QIV.
Next, to account for underlying uncertainty in aTIV rVE
parameter values, results were obtained for three effective-
ness scenarios informed through an assumption in the pub-
lished literature39 and using observational study data37,38. A
scenario analysis in one of the observational studies by
Mannino et al.38 reported a higher aTIV rVE estimate (equal
to 25%) than for the one for HD TIV, issued from an RCT.
Whilst it is possible that the rVE of aTIV exceeds HD TIV, con-
current appraisals suggest it unlikely as: there is direct evi-
dence of increased effectiveness for HD TIV versus aTIV on a
wider outcome including all respiratory hospitalizations; the
scenario analysis by Mannino et al.38 was limited to the
weeks with peak circulating influenza virus which may over-
state effectiveness when compared with the studies con-
ducted over a full influenza season6; and a systematic review
found that only two out of six observational studies identi-
fied statistically significant increases in rVE for aTIV versus SD
TIV22; NACI and ECDC systematic reviews concluded on a
lack of consistent evidence for aTIV superior to SD-TIV.
We were not able to combine GP attendance and hospi-
talization within a single influenza pathway due to differen-
ces in case definitions from the underlying evidence.
Therefore, our decision model was structured to include non-
mutually exclusive pathways where populations could
contract both LCI and attend hospital due to influenza/pneu-
monia. Both pathways were included to avoid underestimat-
ing the cost-effectiveness of HD TIV as both GP visits and
hospitalization are key contributors to the overall health and
economic burden of influenza39,45. We avoided double
counting effects on life years by restricting mortality effects
to the hospitalization pathway. Minimal double counting of
influenza related disutility may have occurred if people had
both LCI and a hospital attendance, however disutility was
not show to impact cost-effectiveness in the DSA. Our deci-
sion model may underestimate cost-effectiveness for HD TIV
as it does not model influenza population transmission. Herd
effects could have been included using a dynamic transmis-
sion model, however, this type of modelling was not
selected given the disparity between data requirements and
data availability.
Due to a lack of available data, vaccine related adverse
events (AEs) were not included in the analysis, but this is not
likely to impact the findings given the strong safety profiles
for both HD TIV52 and aTIV. Furthermore, a recent study has
shown there to be similar safety profiles between both vac-
cines in those aged 65 years and older53. Limited data also
meant the age 65–74 risk groups were only differentiated by
the likelihood of a GP visit following infection. Higher risk
populations may have increased vaccine coverage, hospital-
ization, and mortality rates and therefore grouping param-
eter values may have underestimated the cost-effectiveness
of HD TIV in this sub-population. Furthermore, the HD TIV
cost-effectiveness may have been underestimated for all risk
and age groups as influenza is likely to be linked to several
cardiorespiratory complications that were not included
within the influenza related hospitalization endpoint.
Additionally, the high-risk group was defined as those
with respiratory and heart diseases as these individuals are
likely to experience the biggest impacts of influenza. The
high-risk group could be expanded in future studies to also
include those with diabetes, renal diseases, immunocom-
promised and other chronic conditions, providing there is
sufficient data available to allow for their inclusion in
the analysis.
COVID-19
It should be noted that the inputs collected to feed the cost-
effectiveness model were based on data prior to the COVID-
19 pandemic, and therefore they may change in the forth-
coming years. On one hand, it is possible that public health
measures (e.g. masks, social distancing, and lockdowns)
would decrease the spread of respiratory viruses and result
in higher ICERs (i.e. HD TIV less cost-effective). Furthermore,
by missing two influenza seasons, unpredicted mutations
may result in vaccines that are less effective in general. On
the other hand, due to this absence of influenza virus circula-
tion, a strong epidemic rebound may occur54 that would
decrease the ICERs (i.e. HD TIV more cost-effective).
Moreover, in light of the COVID-19 pandemic, influenza vac-
cine coverage increase (e.g. people more likely to get the
influenza vaccine, and/or co-administration of influenza and
COVID-19 booster) would result in further reduction of ICERs.
Finally, the impact of COVID-19 on future government overall
spending on immunization – and its prioritization – is cur-
rently unknown, as well as how the broader benefits of vac-
cination could be considered when assessing vaccines’ value
for the society. Future work is required to update parameter
values and reassess cost-effectiveness when relevant data
becomes available regarding the impact of the COVID-
19 pandemic.
Conclusion
This is the first study to establish the cost-effectiveness of
HD TIV versus aTIV in a population aged over 65. In the UK,
vaccination with HD TIV instead of aTIV substantially reduced
influenza related GP visits, hospitalizations, and mortality.
The analysis was limited by a lack of robust and consistent
effectiveness data for aTIV, which should be a priority area
for future research.
Notes
i. Further discussion of the non-mutually exclusive pathways is provided in
the Limitations section.
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ii. See Supplementary Material A for detailed methodology.
iii. The rVE estimate of 10% on hospitalization endpoints was applied as
this is the mid-point between the lower and upper values applied in the
base case scenario (0%) and scenario 3 (20%). The proportional increase
in rVE estimates for aTIV on hospitalization endpoints is consistent with
the proportional increase on LCI endpoints across each scenario (0%,
6%, 12%).
iv. Mortality estimates for the scenario analysis were obtained from
published study by Matias et al. (2016)41. who defined hospitalization
due to any respiratory disease using ICD codes J00-99.
v. See Supplementary Material B for full details.
vi. See Table 2 for rVE of aTIV per scenario.
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